二甲双胍联合利拉鲁肽治疗2型糖尿病临床研究

目的：探究二甲双胍联合利拉鲁肽治疗2型糖尿病临床效果,旨在提升临床治疗效果。方法便利选取该院2014年5月—2016年2月收治的120例2型糖尿病患者作为研究对象,采取随机数字表法将所有患者分为对照组(60例)与研究组(60例),对照组所有患者采取单药二甲双胍治疗,研究组患者则采取二甲双胍联合利拉鲁肽治疗,对比两组治疗后临床疗效及不良反应情况、治疗前后BMI指数变化及治疗满意度。结果研究组总有效率高达98.33%,显著高于对照组86.67,差异有统计学意义(P<0.05)；研究组药物不良反应为3.33%,与对照组相当1.67%,差异无统计学意义(P>0.05)。治疗后研究组患者BMI指数明显降低,对照组无变化；研究组治疗总满意率高于对照组,差异有统计学意义(P<0.05)。结论二甲双胍联合利拉鲁肽治疗2型糖尿病疗效良好,患者恢复好,体重减轻,不良反应少,安全性高,满意度高,可推广应用。

Metformin in Combination with the Lalu Peptides in the Treatment of Type 2 Diabetes Clinical Research

Objective Explore metformin combined the lalu peptides in the treatment of type 2 diabetes clinical effect, de-signed to improve the clinical therapeutic effect.Methods Convenient selection from May 2014 to February 2016 were 120 cases of patients with type 2 diabetes as the research object, take a random number table method all patients were divided into control group (60 cases) and group (60 cases) and control group all patients treated with single drug metformin, the team are taking metformin in patients with combined lalu peptide treatment, compared two groups of clinical curative effect and adverse reactions after treatment, BMI change before and after treatment and treatment satisfaction.Results Group total effective rate is as high as 98.33%, significantly higher than control group in 86.67, the difference is statistically significant (P<0.05); Team of adverse drug reactions was 3.33%, and the control group is 1.67%, there was no statistically significant difference(P>0.05). After treatment group patients were significantly lower BMI, the control group no change; The team the overall satisfaction rate is higher than the control group, the difference is statistically significant (P<0.05). Conclusion Met-formin in combination with the lalu peptide treatment curative effect is good, the type 2 diabetes patients restore good, weight loss, less adverse reaction, high safety, satisfaction is high, can be applied.